FDA panel knocks back Spectrum’s bladder cancer drug

An influential group of experts from the FDA has said that small cap Spectrum’s ($SPPI) experimental bladder cancer med Qapzola (apaziquone) isn’t good enough for approval, leaving the treatment’s future hanging in the balance.

The FDA’s advisory committee said Qapzola, which is seeking a license for immediate intravesical instillation post-transurethral resection of bladder tumors, “has not shown substantial evidence of a treatment effect over placebo in patients with non-muscle invasive bladder cancer.”

This is not a final decision and the FDA can decide to go against its committee’s advice, although it typically has followed these in the past. Its PDUFA data is Dec. 11.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The biotech and the FDA have history as in October last year, the regulator rejected its oncology drug, a reformulated take on the chemotherapy melphalan, sold as Alkeran.

But the biotech saw a swift turnaround as in March of this year the FDA allowed the blood cancer med, now known as Evomela, to be sold in the U.S.

Spectrum has also been beset by trial setbacks with Qapzola as back in 2012 two late-stage trials for the med failed to hit their primary endpoints.

The biotech then quickly started a new late-stage study that used input from the FDA and included pooled data from the failed trials. These pooled data, as opposed to those from individual trials, showed a reduction in disease recurrence over two years.

Spectrum fell 8% yesterday on the news, but was up afterhours by nearly 4%, with a market cap just shy of $400 million.

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.